Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definitive treatment

Ended Awarded

Contract number
HT009022FG0210025
Awardee
Awarding agency
Obligated
$18,368

Award facts

Contract value 100% obligated
$18,367.85 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6515 Medical And Surgical Instruments, Equipment, And Supplies
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Sterling, VA, USA

Award details come from SAM.gov/FPDS.

About this award

Sofie CO was awarded a firm fixed price contract by the Defense Health Agency to provide a radiopharmaceutical needed for a prostate cancer patient with metastatic lesions after definitive treatment. The contract has a potential value of $18,367.85 and a period of performance through September 30, 2022. No set-aside designation was used for this award made under the Blanket Purchase Agreement call-ordering procedures. Performance will take place in Sterling, Virginia. The parent company of the prime contractor is Sofie Biosciences, Inc.

Quick answers

Who was awarded contract HT009022FG0210025?

HT009022FG0210025 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on February 28, 2022.

How much is contract HT009022FG0210025 worth?

The government has obligated $18,368 on HT009022FG0210025.

Is contract HT009022FG0210025 an order under another contract?

Yes. HT009022FG0210025 is a BPA call under HT001421A0014, a blanket purchase agreement.

Was contract HT009022FG0210025 competed?

The extent of competition for HT009022FG0210025 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award